This summary was created by AI, based on 4 opinions in the last 12 months.
Boston Scientific Corp (BSX) has demonstrated solid momentum in its business performance, highlighted by a recent acceleration in revenue alongside a history of strategic acquisitions. The company has recently reported impressive financial results, including over 14.7% organic growth, resulting in an optimistic outlook with expected double-digit growth across its product offerings, particularly in minimally invasive surgical devices and the cardiovascular sector. Experts indicated that despite a strong performance and a favorable competitive landscape, particularly due to rival Johnson & Johnson pausing a competing device, the stock currently trades at a high forward Price-to-Earnings (P/E) ratio of 37x. Consequently, while BSX is viewed as a potentially strong long-term investment, market participants are advised to be cautious with aggressive purchases at its current valuation and consider averaging into the stock over time.
They minimally invasive surgical devices, particularly in cardio-vascular, plus medical services. Last year, shares rallied 55% and is up 6% so far this year, thanks to JNJ pausing a competing device. He expects double-digit growth across the entire business, which is rare for pharma.
It just reported a strong revenue beat with over 14.7% organic growth and raise their full-year forecast in earnings and revenues. Was down 1% today in the sell-off, but still worth buying.
Avoid TMO because their revenues are flattening. Both trade at a high PE. BDX hasn't done much in share movement. He'd rather pay more for Boston Scientific which performs better.
Still owns shares. Venture capital fund in health care business. One of most successful funds in biotech. Expecting consistent gains going forward.
Above FMV of $40 by 22%. Growth is fairly nice. He thinks it will hold fairly well. A bouncy kind of stock.
It is at a new high in terms of price but not new highs in terms of Price/Book. There is no yield and a 25% downside risk.
It is a leader in the field so the price is at a premium for a good reason. Has had a good bounce. You could also look at MedTech and Thermo-Fisher.
Boston Scientific Corp is a American stock, trading under the symbol BSX-N on the New York Stock Exchange (BSX). It is usually referred to as NYSE:BSX or BSX-N
In the last year, 4 stock analysts published opinions about BSX-N. 4 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Boston Scientific Corp.
Boston Scientific Corp was recommended as a Top Pick by on . Read the latest stock experts ratings for Boston Scientific Corp.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
4 stock analysts on Stockchase covered Boston Scientific Corp In the last year. It is a trending stock that is worth watching.
On 2025-03-19, Boston Scientific Corp (BSX-N) stock closed at a price of $100.73.
BSX has seen solid momentum recently due to an acceleration in revenue along with a decent track record of acquisitive growth. BSX is trading at 37x Forward P/E and growth is expected to be around 9% in the next few years. That being said, valuation is not cheap. We feel it is a decent name to own over the long term, but we would not be adding aggressively at the current valuation. we are comfortable averaging into BSX over time given the premium valuation it is trading at.
Unlock Premium - Try 5i Free